Virax Biolabs Group Ltd
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Virax Biolabs
In Vitro & In Vivo Diagnostic Substances, SIC 2835
Virax Biolabs Group Limited is a biotechnology company specializing in immune response detection, T-cell immune profiling, and the development of in vitro diagnostic technologies for viral and immune-mediated conditions. The company centers its operations on two core platforms: ViraxImmune, an in-development diagnostic platform targeting post-acute infection syndromes like Long COVID, and ImmuneSelect, a research-use-only portfolio offering peptide pools, ELISpot plates, and related reagents. Its customer base includes academic institutions, research laboratories, contract research organizations, biopharmaceutical companies, independent laboratories, and commercial distributors.
The company operates primarily through operating subsidiaries located across the United Kingdom, the United States, and China. Research and development activities are supported by an internal team of 21 personnel, alongside external clinical and academic research collaborations. Virax Biolabs maintains its principal executive offices at BioCity Glasgow in Newhouse, Lanarkshire, United Kingdom, and is incorporated as an exempted holding company in the Cayman Islands.
Summary of the business section of Virax Biolabs's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Virax Biolabs Group Ltd
- Founded
- 2013
- Headquarters
- Lanarkshire, X0
- Address
- Biocity Glasgow, Bo'Ness Road, Newhouse ML1 5UH
- Phone
- 44 020 7788 7414
- Website
- viraxbiolabs.com
- Industry
- In Vitro & In Vivo Diagnostic Substances
- Incorporated in
- E9
- Fiscal year ends
- March 31
- Auditor
- Reliant CPA PC, Newport Beach, CA
Stock & identifiers
- Ticker
- VRAX
- Exchange
- Nasdaq
- IPO date
- Jul 21, 2022
- Shares outstanding
- 1M, Mar 31, 2026
- Filer category
- Non-accelerated filer<br>Emerging growth company
- Stock splits
- 1-for-25 reverse, Jul 6, 2026; 1-for-25 reverse, Jun 26, 2026; 1-for-10 reverse, Aug 20, 2024; 1-for-10 reverse, Dec 18, 2023; 15-for-4, Jun 14, 2023
- SEC CIK
- 1885827
- CUSIP
- G9495L125
- ISIN
- USG9495L1257
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Nigel William McCracken | Chief Operating Officer, Director | – |
| Jason Davis | Chief Financial Officer | – |
| James Alexander Cunliffe Foster | Chief Executive Officer | 287,987 |
| Nelson M. Haight | Director | – |
| Evan Michael Norton | Director | – |
| Iain David Miller | Director | – |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 1, 2024 | Late filing | Notification of late filing |
| Jul 29, 2022 | Late filing | Notification of late filing |
| Jul 21, 2022 | IPO | Initial public offering priced (424B4 prospectus) |
| Jun 30, 2022 | Listing | Registration of securities on an exchange (Form 8-A) |
| Dec 27, 2021 | Name change | Name changed from Virax Biolabs (Cayman) Ltd to Virax Biolabs Group Ltd |